Adrenomedullin

Cardiovascular / Vasoactive

Also known as: ADM, AM, Adrenomedullin-52

Calcitonin/CGRP SuperfamilyResearch phase: Endogenous peptide (biomarker applications)Regulatory: Endogenous peptide. MR-proADM is an approved biomarker. Adrecizumab (anti-ADM antibody) has been in clinical trials for sepsis.

Mechanism

Adrenomedullin is a 52-amino-acid peptide discovered in a pheochromocytoma tumor that turned out to be an important cardiovascular protector. It is a potent vasodilator, reduces blood pressure, protects the heart and kidneys, and has anti-inflammatory properties. Elevated adrenomedullin levels serve as a biomarker for sepsis severity and heart failure prognosis.

Technical detail

Adrenomedullin (ADM) is a 52-amino-acid peptide with a 6-residue ring structure (disulfide bond) and C-terminal amidation, structurally related to CGRP and amylin. It signals primarily through CLR (calcitonin receptor-like receptor) complexed with RAMP2 (forming the AM1 receptor) or RAMP3 (AM2 receptor), activating Gs-cAMP-PKA and PI3K-Akt-eNOS pathways for vasodilation. Also activates CREB-mediated cytoprotective gene expression. ADM is produced by endothelial cells, VSMCs, and cardiomyocytes. Functions include angiogenesis, lymphatic development, anti-apoptotic effects, and natriuresis. MR-proADM (stable precursor fragment) is used as a sepsis biomarker.

Evidence